AR130983A1 - Derivados de triazinona inhibidores de nlrp3 - Google Patents
Derivados de triazinona inhibidores de nlrp3Info
- Publication number
- AR130983A1 AR130983A1 ARP230102981A ARP230102981A AR130983A1 AR 130983 A1 AR130983 A1 AR 130983A1 AR P230102981 A ARP230102981 A AR P230102981A AR P230102981 A ARP230102981 A AR P230102981A AR 130983 A1 AR130983 A1 AR 130983A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- disorder
- methyl
- condition
- triazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto seleccionado de 6-[[(3R)-1-etil-3-piperidil]amino]-3-(4-hidroxiindan-5-il)-4-metil-1,2,4-triazin-5-ona; 6-[[(3R)-1-etil-3-piperidil]amino]-3-(2-hidroxi-3-biciclo[4.2.0]octa-1,3,5-trienil)-4-metil-1,2,4-triazin-5-ona; 6-[[(3R)-1-etil-3-piperidil]-metil-amino]-3-(4-hidroxiindan-5-il)-4-metil-1,2,4-triazin-5-ona; o una sal farmacéuticamente aceptable de aquel. Reivindicación 6: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4 para su uso en el tratamiento o prevención de una enfermedad, trastorno o afección, en donde la enfermedad, trastorno o afección es sensible a la inhibición de NLRP3. Reivindicación 9: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, para el tratamiento o profilaxis de una enfermedad, trastorno o afección seleccionada de asma o EPOC. Reivindicación 10: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4 para el tratamiento o profilaxis de una enfermedad, trastorno o afección seleccionada de enfermedad de Alzheimer y enfermedad de Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22206287 | 2022-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130983A1 true AR130983A1 (es) | 2025-02-05 |
Family
ID=84330665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102981A AR130983A1 (es) | 2022-11-09 | 2023-11-07 | Derivados de triazinona inhibidores de nlrp3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20260176250A1 (es) |
| EP (1) | EP4615575A1 (es) |
| JP (1) | JP2025537237A (es) |
| KR (1) | KR20250093508A (es) |
| CN (1) | CN120282957A (es) |
| AR (1) | AR130983A1 (es) |
| AU (1) | AU2023376402A1 (es) |
| CL (1) | CL2025001320A1 (es) |
| CO (1) | CO2025005534A2 (es) |
| CR (1) | CR20250186A (es) |
| IL (1) | IL319009A (es) |
| MX (1) | MX2025004961A (es) |
| PE (1) | PE20251675A1 (es) |
| TW (1) | TW202428281A (es) |
| WO (1) | WO2024099996A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| JP2026509587A (ja) * | 2023-03-23 | 2026-03-19 | 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 | トリアジン化合物およびその使用 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021219784A1 (en) * | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
-
2023
- 2023-11-07 JP JP2025526483A patent/JP2025537237A/ja active Pending
- 2023-11-07 AU AU2023376402A patent/AU2023376402A1/en active Pending
- 2023-11-07 WO PCT/EP2023/080902 patent/WO2024099996A1/en not_active Ceased
- 2023-11-07 AR ARP230102981A patent/AR130983A1/es unknown
- 2023-11-07 IL IL319009A patent/IL319009A/en unknown
- 2023-11-07 CR CR20250186A patent/CR20250186A/es unknown
- 2023-11-07 CN CN202380077561.9A patent/CN120282957A/zh active Pending
- 2023-11-07 EP EP23801444.3A patent/EP4615575A1/en active Pending
- 2023-11-07 PE PE2025000975A patent/PE20251675A1/es unknown
- 2023-11-07 KR KR1020257015012A patent/KR20250093508A/ko active Pending
- 2023-11-07 US US19/128,448 patent/US20260176250A1/en active Pending
- 2023-11-08 TW TW112143023A patent/TW202428281A/zh unknown
-
2025
- 2025-04-29 MX MX2025004961A patent/MX2025004961A/es unknown
- 2025-04-30 CO CONC2025/0005534A patent/CO2025005534A2/es unknown
- 2025-05-05 CL CL2025001320A patent/CL2025001320A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025001320A1 (es) | 2025-07-11 |
| JP2025537237A (ja) | 2025-11-14 |
| AU2023376402A1 (en) | 2025-02-13 |
| CO2025005534A2 (es) | 2025-05-19 |
| MX2025004961A (es) | 2025-06-02 |
| IL319009A (en) | 2025-04-01 |
| KR20250093508A (ko) | 2025-06-24 |
| US20260176250A1 (en) | 2026-06-25 |
| CR20250186A (es) | 2025-06-26 |
| CN120282957A (zh) | 2025-07-08 |
| TW202428281A (zh) | 2024-07-16 |
| PE20251675A1 (es) | 2025-06-30 |
| WO2024099996A1 (en) | 2024-05-16 |
| EP4615575A1 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007192A (es) | Inhibidores de prmt5. | |
| GEP20257750B (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| PE20251675A1 (es) | Derivados de triazinona como inhibidores de nlrp3 | |
| MX2021015262A (es) | Inhibidores de prmt5. | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| MX2007013216A (es) | Derivados de amida substituida como inhibidores de la proteina de cinasa. | |
| MA30208B1 (fr) | Derives de pyrimidine utilises en tant qu'inhibiteurs de kinase pi -3 | |
| CR9984A (es) | Método de inhibición de cinasa de tirosina cinasa 3 similar a fms | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| EA201170061A1 (ru) | Новые производные фенилимидазола в качестве ингибиторов фермента pde10a | |
| EA201171213A1 (ru) | Ингибитор р38 мар киназы | |
| MA29799B1 (fr) | Administration d'inhibiteurs de dipeptidyl peptidase | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| PH12019502601A1 (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| BRPI0607433A2 (pt) | composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto | |
| MX2018014425A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| JOP20250208A1 (ar) | مشتقات فينيل بيبريدين كمثبطات لبروتين ربط جلوتامينيل - ببتيد سيكلو ترانسفيراز وجلوتامينيل - ببتيد سيكلو ترانسفيراز | |
| MX2021012392A (es) | Compuestos, composiciones y metodos. | |
| UA107106C2 (uk) | УРЕТАНИ, СЕЧОВИНИ, АМІДИ ТА РОДИННІ ІНГІБІТОРИ ФАКТОРА Xа |